CBAY - Cymabay Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed price. Currency in USD
14.98
+0.11 (+0.74%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close14.87
Open14.85
Bid11.54 x 500
Ask12.83 x 1000
Day's range14.53 - 15.25
52-week range2.77 - 15.25
Volume1,400,549
Avg. volume826,254
Market cap830.592M
Beta2.92
PE ratio (TTM)N/A
EPS (TTM)-1.00
Earnings date21 Mar 2018 - 26 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.63
Trade prices are not sourced from all markets
  • MarketWatch5 days ago

    4 charts to watch as tech stocks rebound

    In focus: CymaBay Therapeutics, Mimecast, Match Group and Twitter. By Harry Boxer.

  • Globe Newswire21 days ago

    CymaBay Announces Proposed Public Offering of Common Stock

    CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by CymaBay. CymaBay intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering.

  • Globe Newswirelast month

    CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America

    CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced it has received a $5 million milestone payment from Kowa Pharmaceuticals America for the initiation of a study evaluating the pharmacokinetics (PK) of arhalofenate in subjects with renal impairment. “We are pleased with Kowa’s continued commitment to advancing the development of arhalofenate for patients with gout,” said Sujal Shah, President and Chief Executive Officer of CymaBay.  “The initiation of the renal PK study is a key step toward Phase 3 development.

  • Globe Newswire2 months ago

    CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

    NEWARK, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that Sujal Shah, President and Chief Executive Officer, will provide a corporate overview at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11, 2018 at 9:30am PT.

  • Forbes2 months ago

    BlackBerry Among Four Stocks Breaking Out

    Here are four stocks showing strong technical momentum.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes